The antagonists of the angiotensin receptors II (ARAII) in diabetic nephropaty;Los antagonistas de los receptores de la angiotensina II (ARAII) en la nefropatía diabética

MEDIFAM - Revista de Medicina Familiar y Comunitaria

Volumn 12, Issue 7, 2002, Pages 421-425

  Delgado, R ^a   Aguilera, A ^a  

^a HOSPITAL RUBER INTERNACIONAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIURETIC AGENT; IRBESARTAN; LOSARTAN; PLACEBO; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MICROALBUMINURIA; PROTEINURIA; PUBLICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

EID: 0036638406     PISSN: 11315768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (29)

1. Renal failure in diabetic nephropaty
2. Intercapilar lesions in glomeruli of kidney
3. Similar risks of nephropaty in patients with type I or type II diabetes mellitus
4. Distribution of primary renal disease leading to end-stage failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study
5. Comparación de la incidencia, prevalencia, modalidades de tratamiento y mortalidad en pacientes con tratamiento renal sustitutivo en cinco comunidades autónomas españolas en el periodo 1991-1996
6. The stage in diabetic nephropaty
7. Increased kidney size and GFR in untreated juvenile diabetes: Normalization by insulin treatment
8. Collagen againg in vitro by nonezimatic glycosylation and browning
9. Non-enzymatic glicosylation of urinary proteins in type I insulin dependient diabetes: Correlation with metabolic control and degree of proteinuria
10. Aldose reductase in the etiology of diabetic complications nephropaty
11. Efects of sorbitol on glomerular structure and function in long-term diabetic rats
12. Mechanism of the progression of diabetic nephropaty to renal failure
13. Predisposition to hypertension and susceptibility to renal disease in insulin dependientdiabetes mellitus
14. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropaty
15. Prostaglandins, angiotensin II and proteinuria
16. Increase renal production of transforming grown factor-β in patients with type II diabetes
17. Losartan decrease plasma levels of TGF-b in trasplant patients with chronic allograft nephropaty
18. Captopril-induced reduction of serum levels of transforming grown factor beta correlates with long-term renoprotecction in insulin-dependient diabetic patients
19. Chronic renal failure: Pathophysiology
20. Long-term antihypertensive treatment inhibiting progression of diabetic nephropaty
21. Safety and efficacy of irbesartan in hypertensive patients with Type II diabetes and proteinuria
22. Renoprotective effect of the angiotensin receptor antagomist Irbesartan in patients with nephropatie due to diabetes type II
23. The effect of irbesartan on the development of diabetic nephropaty in patients with type 2 diabetes
24. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropaty
25. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with no-insulin-dependent diabetes and hypertension
26. Antiproteinuric effect of blood-pressure-lowering agents; A meta-analysis of comparative trials
27. Effects of diferent antihypertensive treatments on morfologic progression of diabetic nephropaty in uninphrectomized dogs
28. Prevention of end-estage renal disease due to type 2 diabetes
29. Clinical comparative trials of angiotensin II type (AT1)-receptor blockers